Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Cancer|October 4, 2021
Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional studyVirginie Nerich, Christophe Guyeux, Michel Henry-Amar, et al.
Leukemia|May 24, 2019
A revised international prognostic score system for Waldenström's macroglobulinemiaEfstathios Kastritis, Pierre Morel, Alain Duhamel, et al.
NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.
Eclinicalmedicine|April 1, 2025
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSAClémentine Sarkozy, Thierry Jo Molina, Sydney Dubois, et al.
Blood Advances|July 17, 2020
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE studyMarie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, et al.
The Lancet. Oncology|November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialCarsten U Niemann, Talha Munir, Carol Moreno, et al.
Blood|February 26, 2026
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHLPaul Marcoux, Fabien Gava, Marie Tosolini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW StudyTalha Munir, Carol Moreno, Carolyn Owen, et al.
Blood|March 14, 2019
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemiaIan W Flinn, John G Gribben, Martin J S Dyer, et al.
Blood Advances|November 12, 2020
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaLaetitia Vercellino, Roberta Di Blasi, Salim Kanoun, et al.
Pageof 7